Cerebral Prescription and Intake Process: How It Works, What to Expect

How the Cerebral Intake Process Works

Cerebral's intake begins with an online self-assessment covering symptom history, current medications, medical history, and treatment goals. This questionnaire draws from validated screening instruments including the PHQ-9 for depression and the GAD-7 for anxiety [1][2]. Patients answer approximately 50 to 80 questions depending on their presenting concerns.

After completing the questionnaire, patients select a subscription tier and schedule their first video appointment. Cerebral assigns a prescriber based on state licensure, availability, and the patient's clinical needs. The company operates across all 50 states, though prescriber availability and medication options vary by jurisdiction. In states with stricter telehealth regulations for controlled substances, patients may face longer wait times or additional requirements before receiving stimulant medications. The DEA's 2023 extension of COVID-era telehealth flexibilities allows initial prescriptions of Schedule II substances via video visit without an in-person exam in most states [3].

What Happens During the First Video Visit

The initial prescriber appointment runs 30 to 45 minutes. Your clinician reviews the intake questionnaire, asks follow-up questions, performs a mental status examination via video, and discusses treatment options including both medication and therapy.

For straightforward presentations of generalized anxiety or major depressive disorder, prescribers commonly initiate first-line medications during this visit. SSRIs like sertraline (Zoloft) and escitalopram (Lexapro) remain the standard starting point, consistent with APA Practice Guidelines recommending SSRIs or SNRIs as initial pharmacotherapy for major depressive disorder [4]. Buspirone for anxiety and hydroxyzine for acute symptom relief are also frequently prescribed during the first encounter.

ADHD evaluations require more documentation. Cerebral's process involves additional screening with instruments modeled on the Adult ADHD Self-Report Scale (ASRS-v1.1), a WHO-developed tool with 68.7% sensitivity and 99.5% specificity for adult ADHD when using the six-item screener [5]. Prescribers may request prior records, school documentation, or collateral information before initiating stimulant therapy.

Medications Cerebral Prescribes

Cerebral prescribers have access to a broad formulary spanning multiple medication classes. The platform does not publicly restrict its formulary to specific agents, though individual prescribers exercise clinical judgment about appropriateness.

Common prescriptions include SSRIs (sertraline, escitalopram, fluoxetine), SNRIs (venlafaxine, duloxetine), atypical antidepressants (bupropion), anxiolytics (buspirone, hydroxyzine), and sleep aids (trazodone). For ADHD, stimulant options include methylphenidate formulations and mixed amphetamine salts, along with non-stimulant alternatives like atomoxetine and guanfacine extended-release.

A 2022 retrospective analysis published in JAMA Network Open found that telemental health visits resulted in comparable prescribing patterns to in-person psychiatric encounters, with no significant difference in medication class selection or dosing for depression and anxiety [6]. This suggests that the virtual format itself does not inherently compromise prescribing quality. The determining factor remains prescriber training, clinical acumen, and adequate time spent with each patient.

Benzodiazepines are generally not initiated through Cerebral's platform, aligning with current guidelines from the American Psychiatric Association that recommend against benzodiazepines as first-line treatment for anxiety disorders given dependence risk and cognitive effects [4].

Clinical Safeguards and Limitations

Cerebral implements several safeguards within its intake and prescribing workflow. Patients complete standardized screening tools at each visit, enabling clinicians to track symptom trajectories over time using validated measures. The PHQ-9 has demonstrated 88% sensitivity and 88% specificity for major depression at a cutoff score of 10 [1].

Prescription drug monitoring program (PDMP) checks are required before controlled substance prescriptions in all states that mandate them. Cerebral's prescribers must query the state PDMP database, which tracks dispensing of Schedule II through V medications, before writing stimulant prescriptions. This mirrors in-person practice standards established by state medical boards.

The platform has limitations. Patients in acute psychiatric crisis, those with active suicidal ideation with plan and intent, or those requiring medication combinations that demand close laboratory monitoring (lithium, clozapine) are typically referred to in-person care. Cerebral cannot perform physical examinations, order labs directly in most states, or provide emergency psychiatric services. The 2021 Endocrine Society position statement on telemedicine notes that virtual care works best for conditions where diagnosis relies primarily on clinical interview rather than physical findings [7]. Psychiatric prescribing fits this model well for most outpatient presentations.

Cerebral's Regulatory History and Current Standing

Any honest assessment of Cerebral must address the company's regulatory scrutiny. In 2022, the DOJ and DEA investigated Cerebral's controlled substance prescribing practices, particularly around stimulant medications [8]. The company subsequently tightened its ADHD prescribing protocols, added mandatory PDMP checks in states where they were not yet required, and implemented prescriber oversight committees.

The FDA's 2023 Drug Safety Communication on stimulant medications emphasized that all prescribers, whether in-person or telehealth, must conduct thorough evaluations before initiating these medications [9]. Cerebral now requires a minimum 30-minute initial evaluation specifically for ADHD, documentation of functional impairment in at least two life domains, and consideration of alternative diagnoses before stimulant initiation.

CVS Health's 2022 decision to temporarily halt filling Cerebral's controlled substance prescriptions drew significant media attention. CVS subsequently resumed filling these prescriptions after Cerebral implemented additional clinical protocols. This episode highlighted broader tensions in telehealth prescribing rather than issues unique to Cerebral alone. A 2023 analysis in the Annals of Internal Medicine found that telehealth stimulant prescribing increased 25.8% between 2020 and 2022 across all platforms, not solely Cerebral [10].

Cost Structure and Insurance Coverage

Cerebral operates on a monthly subscription model with three primary tiers. The medication management plan (prescriber visits only) costs approximately $85 per month. Adding therapy sessions increases the monthly fee to $259 to $325 depending on visit frequency. These prices reflect 2025 cash-pay rates and do not include medication costs.

Insurance coverage meaningfully reduces out-of-pocket expenses. Cerebral accepts most major commercial insurers including Aetna, Cigna, UnitedHealthcare, and many Blue Cross Blue Shield plans. With insurance, copays for prescriber visits typically range from $0 to $30 per visit. A 2023 systematic review in Psychiatric Services found that the average cost of an in-person initial psychiatric evaluation ranged from $250 to $500 without insurance [11]. Cerebral's cash-pay pricing undercuts this substantially for the medication management tier.

Medication costs are separate from the subscription. Generic SSRIs average $4 to $15 per month at major pharmacies. Generic stimulants range from $30 to $80 monthly. Brand-name ADHD medications (Vyvanse, Concerta) can exceed $300 without insurance, though manufacturer coupons and insurance coverage reduce this significantly.

Cerebral vs. Alternative Telemental Health Platforms

The telemental health market includes several direct competitors: Done, Talkiatry, Brightside, and Ahead. Each platform differs in prescriber qualifications, wait times, and medication access.

Talkiatry exclusively employs board-certified psychiatrists (MDs/DOs with completed residency), while Cerebral uses a mix of psychiatric nurse practitioners and psychiatrists. A 2020 meta-analysis in the Journal of Clinical Psychiatry found no statistically significant difference in patient outcomes between NP-managed and physician-managed psychiatric medication management for depression and anxiety [12]. For complex cases involving treatment resistance, multiple comorbidities, or polypharmacy, psychiatrist-level training may provide additional clinical value.

Done (now rebranded) faced even more intense DEA scrutiny than Cerebral, with its co-founder indicted in 2024 on federal charges related to stimulant distribution. This context matters when evaluating platform legitimacy. Cerebral was investigated but not charged, and has since implemented substantive protocol changes.

Brightside focuses exclusively on depression and anxiety without offering ADHD treatment or controlled substances. This narrower scope reduces regulatory risk but limits utility for patients with multiple conditions. Ahead positions itself specifically for ADHD but operates in fewer states than Cerebral.

Wait times represent a practical differentiator. The average wait for a new-patient in-person psychiatry appointment in the United States exceeds 25 days according to a 2022 Merritt Hawkins survey [13]. Cerebral typically offers first appointments within 3 to 7 days, a meaningful advantage given that treatment delays correlate with worsening outcomes in depressive episodes.

Effectiveness of Online Psychiatric Prescribing

Does the telehealth format compromise treatment quality? Available evidence suggests not for most outpatient psychiatric conditions. A 2021 Cochrane review of videoconferencing for mental health found comparable outcomes between video-delivered and in-person psychiatric care for depression, with moderate-certainty evidence supporting non-inferiority [14].

The STAR*D trial (N=4,041) established that remission rates for major depression with first-line SSRI therapy reach approximately 33% regardless of care setting [15]. What matters most is adequate dosing, sufficient trial duration (6 to 8 weeks at therapeutic dose), and systematic follow-up. These elements are achievable through virtual platforms when structured properly.

For ADHD specifically, a 2022 randomized controlled trial published in JAMA Psychiatry (N=221) found that telehealth-delivered ADHD assessment and management produced equivalent improvements in ADHD-RS-IV scores compared to in-person care at 12 months [16]. Symptom reduction averaged 12.4 points in the telehealth group versus 13.1 points in the in-person group, a non-significant difference (p=0.71).

Monthly follow-up visits through Cerebral allow prescribers to adjust medications based on response and tolerability. This cadence aligns with APA guidelines recommending contact every 1 to 4 weeks during active treatment optimization [4]. Patients who do not respond adequately to initial therapy can be switched to alternative agents or referred to in-person care for treatment-resistant presentations.

Who Should and Should Not Use Cerebral

Cerebral works well for adults with uncomplicated anxiety, depression, insomnia, or ADHD who want convenient access to psychiatric medication management without long wait times. Patients already stabilized on medications who need ongoing prescriptions and monitoring also benefit from the platform's accessibility.

Cerebral is not appropriate for patients with psychotic disorders, active substance use disorders requiring supervised withdrawal, personality disorders requiring intensive dialectical behavior therapy, eating disorders with medical instability, or bipolar disorder requiring complex mood stabilizer management with regular lab monitoring. The platform's own intake process screens for these conditions and redirects patients toward appropriate care settings.

Patients prescribed stimulants through Cerebral should expect ongoing monitoring including heart rate and blood pressure checks (self-reported or via primary care), weight tracking, and periodic reassessment of continued need. The American Academy of Child and Adolescent Psychiatry guidelines for stimulant prescribing, while written for pediatric populations, establish monitoring standards that responsible adult prescribers also follow [17].

The bottom line: Cerebral's 30-minute initial evaluation paired with validated screening instruments, PDMP checks, and monthly follow-up represents adequate clinical infrastructure for routine outpatient psychiatric prescribing. Start your intake questionnaire during a time when you can answer honestly and thoroughly, as the quality of your self-reported history directly determines the quality of your prescriber's clinical decision-making.